Immunotherapy with adoptive cytomegalovirus‐specific T cells transfer: Summarizing latest gene engineering techniques

Mehdizadeh, Mahshid; Karami, Samira; Nazari, Haniyeh Ghaffari; Sankanian, Ghazaleh; Hamidpour, Mohsen; Hajifathali, Abbas

doi:10.1002/hsr2.322

Cited by 5 publications

(4 citation statements)

References 97 publications

(133 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, T cells can be genetically modified to recognize antigens independent of the major histocompatibility complex (MHC) and retain their protective functions during simultaneous treatments. 28 The use of engineered T cells, specifically CAR-T cells, to treat CMV was first investigated in 2016. 29 Recently, Olbrich et al engineered T cells with a CAR-T that specifically targeted the human CMV glycoprotein B (gB) molecule, which is expressed during viral reactivation.…”

Section: Resultsmentioning

confidence: 99%

Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023

Sun,

Li,

Chen

2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Recently, the remarkable success of chimeric antigen receptor T cell (CAR-T) therapy in treating certain tumors has led to numerous studies exploring its potential application to treat non-oncology diseases. This review discusses the progress and evolution of CAR-T cell therapies for treating non-oncology diseases over the past 5 years. Additionally, we summarize the advantages and disadvantages of CAR-T cell therapy in treating non-oncological diseases and identify any difficulties that should be overcome. After conducting an in-depth analysis of the most recent studies on CAR-T technology, we discuss the key elements of CAR-T therapy, such as developing an effective CAR design for non-oncological diseases, controlling the rate and duration of response, and implementing safety measures to reduce toxicity. These studies provide new insights into different delivery strategies, the discovery of new target molecules, and improvements in the safety of CAR-T therapy for non-oncological diseases.

show abstract

Section: Resultsmentioning

confidence: 99%

Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023

Sun,

Li,

Chen

2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Immune monitoring via quantification of HCMV-specific T-cell responses is used to identify patients at high risk for future prolonged and symptomatic HCMV reactivation. This allows for personalized and targeted treatment of this high-risk group, 35 , 36 decreasing morbidity and mortality among allo-SCT recipients. 37 , 38 A lack of available peptides results in incorrect high-risk classifications of allo-SCT recipients, especially among patients with rare HLA haplotypes.…”

Section: Discussionmentioning

confidence: 99%

Identification of novel canonical and cryptic HCMV-specific T-cell epitopes for HLA-A∗03 and HLA-B∗15 via peptide-PRISM

Rein,

Lauruschkat,

Muchsin

et al. 2024

Blood Advances

View full text Add to dashboard Cite

Human cytomegalovirus (HCMV) reactivation poses a substantial risk to transplant patients. Effective risk stratification and vaccine development is hampered by a lack of HCMV-derived immunogenic peptides in patients with common HLA-A*03:01 and HLA-B*15:01 haplotypes. This study aimed to discover novel HCMV immunogenic peptides for these haplotypes by combining Ribo-seq and mass spectrometry with state-of-the-art computational tools, Peptide-PRISM and PRICE. Furthermore, employing machine learning, an algorithm was developed to predict immunogenicity based on translational activity, binding affinity and peptide localization within small open reading frames to identify the most promising peptides for in vitro validation. Immunogenicity of these peptides was subsequently tested by analyzing peptide-specific T-cell responses of HCMV-seropositive and -seronegative healthy donors as well as transplant patients. This resulted in the direct identification of three canonical and one cryptic HLA-A*03-restricted immunogenic peptides as well as five canonical and one cryptic HLA-B*15-restricted immunogenic peptide, with a specific IFNγ+/CD8+ T-cell response of ≥ 0.02%. High T-cell responses were detected against two HLA A*03-restricted and three HLA-B*15-restricted canonical peptides with frequencies of up to 8.77% IFNγ+/CD8+ T cells in patients post alloSCT. Therefore, our comprehensive strategy establishes a framework for efficient identification of novel immunogenic peptides from both existing and novel Ribo-seq datasets.

show abstract

“…107 Optimal therapy depends on identification of CMV immunodominant antigens, frequency of CMV-specific T-cell subsets in the graft, and cell isolation and enrichment techniques. 108 Data surrounding this therapeutic approach have been largely dominated by stem cell transplant recipients with limited studies or reports in SOT recipients. 109 Hesitancy around its use in SOT patients relates to the persistent attenuation of T-cell function produced by immunosuppressive medication.…”

Section: Cmv-specific T-cell Therapymentioning

confidence: 99%

What’s New: Updates on Cytomegalovirus in Solid Organ Transplantation

Stewart,

Kotton

2023

Transplantation

View full text Add to dashboard Cite

Cytomegalovirus (CMV) is one of the most common infections occurring after solid organ transplantation. This high burden of disease, which incurs sizeable morbidity, may be worsening with the proportion of high-risk D+/R− solid organ transplantation recipients increasing in some regions globally. Cohort studies continue to support either universal prophylaxis or preemptive therapy as effective prevention strategies. Letermovir prophylaxis was noninferior to valganciclovir in adult high-risk D+/R− kidney transplant recipients with fewer drug-related adverse events in a recent clinical trial and has now been approved for such use in some regions. Maribavir preemptive therapy failed to demonstrate noninferiority when compared with valganciclovir in hematopoietic stem cell transplant recipients but looked promising for safety. Donor matching could be useful in prevention CMV disease with a survival advantage demonstrated in seronegative recipients waiting up to 30 mo for a seronegative kidney. Immune-guided prophylaxis resulted in fewer CMV infection episodes in lung transplant recipients when compared with fixed-duration prophylaxis in a recent clinical trial. For treatment of refractory or resistant CMV infection, maribavir was more efficacious and better tolerated when compared with investigator-initiated therapy in its registration trial for this condition. Further research regarding best treatment and prophylaxis of resistant or refractory CMV infection is needed to reflect best clinical practice choices. Optimal use of immune globulin or CMV-specific T cells for prevention or treatment of CMV disease remains undefined. Standardized definitions for the design of CMV clinical trials have been developed. In this review, we highlight recent updates in the field from data published since 2018.

show abstract

Immunotherapy with adoptive cytomegalovirus‐specific T cells transfer: Summarizing latest gene engineering techniques

Cited by 5 publications

References 97 publications

Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023

Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023

Identification of novel canonical and cryptic HCMV-specific T-cell epitopes for HLA-A∗03 and HLA-B∗15 via peptide-PRISM

What’s New: Updates on Cytomegalovirus in Solid Organ Transplantation

Contact Info

Product

Resources

About